‘You disappointed us’: Why is Canada opposing more transparency in drug prices? | CBC News
The fact that transparency is even on the agenda for government
health officials at the WHA is evidence of the mounting international
frustration over high drug prices. The meeting sets priorities for the
World Health Organization (WHO), which is already grappling with the global impact of drug prices on public health.
health officials at the WHA is evidence of the mounting international
frustration over high drug prices. The meeting sets priorities for the
World Health Organization (WHO), which is already grappling with the global impact of drug prices on public health.
Pharmaceutical
companies have long insisted that high prices are necessary to cover
research and development (R&D) costs and keep them in business.
But
with increasing numbers of new drugs priced at hundreds of thousands of
dollars per patient per year, some countries are demanding to see the
industry’s financial data.
The WHA’s transparency resolution
would demand unprecedented disclosure by drug companies about how much
they spend on R&D, including the cost of clinical trials.